New Market Research Report: Algeria Pharmaceuticals & Healthcare Report Q3 2016

The Algerian pharmaceutical market will remain attractive to multinational drugmakers , despite the slow pace of improvements in the regulatory and market access environment. Key market drivers such as growing demand for healthcare , rising chronic disease burden and sustained foreign investment in domestic drug manufacturing will continue to translate in strong market growth rates over the forecast period. Despite short-term economic and fiscal challenges, developing Algeria's pharmaceutical industry will remain a policy priority and therefore benefit from government incentives . This will remain in line with the broader interest by foreign drugmakers to sustain the country ' s ongoing plan to become a regional hub in pharmaceutical production.

Full Report Details at
- http://www.fastmr.com/prod/1152813_algeria_pharmaceuticals.aspx?afid=301

Headline Expenditure Projections

Pharmaceuticals: DZD411.62bn (USD4.12bn) in 2015 to DZD451.90bn (USD4.13bn) in 2016; +9.8% in local currency and +0.3% in US dollar terms. Forecast in line with last quarter .
Healthcare: DZD1.11trn (USD11.14bn) in 2015 to DZD1.20trn (USD11.00bn) in 2016; +8.2% in local currency and -1.2% in US dollar terms. Forecast in line with last quarter .

Risk/Reward Index

In Q316, we have revised Algeria's Pharmaceutical Risk/Reward Index (RRI) score upwards to 50.8 (out of 100) from 50.4 previously. This is above the regional average of 41.3. The score revision was driven by improved country risks indices. Algeria remains in eighth place out of 31 countries in the Middle East and Africa region in BMI's proprietary RRI matrix. Algeria's score is boosted by a large pharmaceutical market and a favourable long-term market development, but dragged down by the country's poor regulatory environment.

Latest Updates

March 2016

On occasion of the Algerian-US Forum organised by the US-Algeria Businessmen Council and the Pharmaceutical Research and Manufacturers of America (PhRMA), US ambassador to Algiers, Joan Polaschik, highlighted that US pharmaceutical firms are carrying out nine out of 48 investment projects currently underway in the Sidi Abdellah life sciences and industrial park in Algeria, while confirming the US' commitment to providing assistance to Algeria in developing its pharmaceutical industry.

Algeria's participation as a guest of honour at the Tunisia International Health Expo in Tunis provided an opportunity for health operators and stakeholders to promote mechanisms to facilitate complementarity in the pharmaceutical and medical equipment industries between Algeria and Tunisia, signalling the potential strengthening of markets integration.

Algeria's Prime Minister Abdelmalek Sellal confirmed the agreement to launch the construction of a 240-bed hospital in the province of Tamanrasset and a 120-bed hospital in the sub-province of In Salah, which are 'major public projects that are not concerned by cancellation and freezing measures', reports Algeria Press Service.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)